他克莫司在非移植患者中的群体药代动力学研究现状  

Research status of population pharmacokinetics of tacrolimus in patientsswith non-transplant diseases

作　　者：郑媛媛 苑钰洁 傅姝萌 黄晓茹 赵维 郝国祥 ZHENG Yuan-yuan;YUAN Yu-jie;FU Shu-meng;HUANG Xiao-ru;ZHAO Wei;HAO Guo-xiang(Department of Clinical Pharmacy,School of Pharmaceutical Sciences,Cheeloo College of Medicine,Shandong University,Jinan 250012,Shandong Province,China)

机构地区：[1]山东大学齐鲁医学院药学院临床药学系,山东济南250012

出　　处：《中国临床药理学杂志》2024年第22期3358-3362,共5页The Chinese Journal of Clinical Pharmacology

基　　金：国家重点研发计划基金资助项目(2020YFC2008303,2020YFC2008306);国家自然科学基金资助项目(81503163)。

摘　　要：他克莫司是目前器官移植后的一线免疫抑制药物,同时也应用于很多非移植疾病的治疗。由于他克莫司个体差异大,治疗窗窄,个体化给药研究非常有必要。群体药代动力学在个体化给药方面具有很大优势。本文旨在总结他克莫司在非移植性疾病患者中的群体药代动力学及其影响因素研究,探讨他克莫司在非移植患者中的个体化治疗,为临床合理用药提供参考。Tacrolimus is the first immunosuppressive choice for organ transplantation.It is also used in the immunotherapy of many non-transplant diseases.Because of its large individual variabilities and narrow treatment window,the individualized administration for tacrolimus taking advantage of population pharmacokinetics is necessary.This article aims to summarize population pharmacokinetics studies of tacrolimus in patients with non-transplant diseases and its influencing factors,and to provide a reference for rational use of tacrolimus.

关 键 词：他克莫司 群体药代动力学 儿童 非移植性疾病 个体化用药 

分 类 号：R979.5[医药卫生—药品]